Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | CEP-701 | FIMM | pan-cancer | AAC | -0.048 | 0.7 |
mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.066 | 0.7 |
mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | BIRB 0796 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.7 |